PCSK9 Reassures in Longest-Term Data Yet for FH

]]>(MedPage Today) -- Safety of starting young patients with familial hypercholesterolemia on evolocumab (Repatha) was upheld by over 4 years of data, the most published to date for any PCSK9 inhibitor in this group.Out of 300 adolescents and adults...